1-6 of 6
Mounzer E Agha
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Christiane A. Houde, Abdullah Khan, Susanna J. Jacobus, Hani Hassoun, Larry D. Anderson, Jr., Lauren E. Merz, Rebecca L. Zon, Yvonne Efebera, Tondre Buck, Racquel D. Innis-Shelton, Monique A Hartley-Brown, Sagar Lonial, Erica L. Campagnaro, Peter M. Voorhees, Robert Z. Orlowski, Edward Libby, David Duane Hurd, Caitlin L. Costello, Noopur S. Raje, Eva Medvedova, Philip L. McCarthy, Carter P. Milner, Cristina Gasparetto, Mounzer E Agha, Krisstina Gowin, Rammurti T. Kamble, Sundar Jagannath, Nitya Nathwani, Melissa Alsina, Sergio A. Giralt, Jacob P. Laubach, Omar Nadeem, Irene M. Ghobrial, Clifton C. Mo, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Paul G. Richardson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2023-181032
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Single Agent Gemtuzumab Ozogamicin (Mylotarg) Can Induce Hematologic Remissions in Patients with Refractory Acute Myelogenous Leukemia (AML) Relapse Following Allogeneic Stem Cell Transplantation but May Precipitate Acute Graft-Versus-Host Disease (GVHD).

Mounzer E. Agha, MD, Anastasios Raptis, MD, Sarah B. Miller, Michelle Taylor, Markus Y. Mapara, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 5405.
https://doi.org/10.1182/blood.V106.11.5405.5405
Published: 2005
Journal Articles

Single Agent Gemtuzumab Ozogamycin (Mylotarg) Is Effective in Inducing Hematologic Remission in Elderly Patients with Normal Cytogenetics.

Mounzer E. Agha, MD, Miller Sarah, PA-C, Howard Kirkland, MD, Theodore L. Crandall, MD, John W. Mucenski, PharmD.
Journal: Blood
Blood (2004) 104 (11): 4402.
https://doi.org/10.1182/blood.V104.11.4402.4402
Published: 2004
Journal Articles

Outpatient High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Is Associated with a Low Infection Safety Profile.

Mounzer E. Agha, M.D., Andrew M. Yeager, M.D., Carol Evans, M.D., Nikol Borkowski, P.A.-C., Anne Marie Scekeres, R.N., Sarah Miller, P.A.-C., Cheryl Tompkins, C.R.N.P., Rowena Schwartz, Pharm.D., Albert D. Donnenberg, Ph.D., Jeffrey Shogan, M.D.
Journal: Blood
Blood (2004) 104 (11): 5070.
https://doi.org/10.1182/blood.V104.11.5070.5070
Published: 2004
Journal Articles

Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.

Michael P. Carroll, M.D., Diane BuchBarker, M.D., Rowena Schwartz, Pharm.D., Mounzer E. Agha, M.D., Cheryl Tompkins, C.R.N.P., Kristen Baileys, C.R.N.P., Kathleen O’Connell, R.N., Albert D. Donnenberg, Ph.D., Andrew M. Yeager, M.D.
Journal: Blood
Blood (2004) 104 (11): 5165.
https://doi.org/10.1182/blood.V104.11.5165.5165
Published: 2004